AlphaMadera's AlphaVal page computes Akoya Biosciences, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag AKYA as undervalued, fairly valued, or overvalued.

What is Akoya Biosciences, Inc.'s fair value?

Fair value for AKYA is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value AKYA?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from AKYA's most recent reported fundamentals.

AKYA - Akoya Biosciences, Inc.

Price: -- --

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

Need at least 2 years of income statements for AKYA